Biogen Idec Inc (BIIB) 422.24 $BIIB
Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 51 mins ago
Biogen (BIIB) announced that the European Medicines Agency has accepted its biosimilar candidate SB2 for review.
BIIB: 422.24 (-9.38), CBM: 39.63 (+4.04), HSP: 87.84 (+0.12), NVS: 98.61 (-2.70)
Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
PR Newswire Europe - Tue Mar 31, 11:52AM CDT
DUBLIN, Mar. 30, 2015 /PRNewswire/ --Research and Markets
JNJ: 100.60 (-0.95), BIIB: 422.24 (-9.38)
Healthcare Hedge Fund Orbimed's Top Picks And New Move
Insider Monkey - Seeking Alpha - Tue Mar 31, 10:37AM CDT
By Usman Rafi According to a Schedule 13D Form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) by about 14%. The fund...
BIIB: 422.24 (-9.38), ICPT: 282.02 (-13.89), AMGN: 159.85 (-4.45), BMY: 64.50 (-1.26)
Insider Trading Alert - MTEX, BDL And BIIB Traded By Insiders
at The Street - Tue Mar 31, 9:15AM CDT
Stocks with insider trader activity include MTEX, BDL and BIIB
BIIB: 422.24 (-9.38), MTEX: 18.76 (+0.35), BDL: 32.01 (unch)
Strong Dollar Hurts Profit Forecasts In Long Term
Orit Nathan Mahalal - at Seeking Alpha - Tue Mar 31, 7:00AM CDT
BIIB: 422.24 (-9.38), ABX: 10.96 (-0.18), FB: 82.21 (-0.98), IBB: 343.43 (-7.89), GOOG: 548.00 (-4.03), UUP: 25.90 (+0.04), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), KGC: 2.24 (-0.05), GLD: 113.66 (-0.09), ALXN: 173.30 (-6.96), DIA: 177.58 (-1.81), XLK: 41.44 (-0.43), GOOGL: 554.70 (-6.44), FXE: 105.71 (-0.61), IWM: 124.37 (-0.40), MSFT: 40.65 (-0.31), AAPL: 124.43 (-1.94), REGN: 451.48 (-8.30), GG: 18.12 (-0.07)
Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 5:09PM CDT
Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency has validated the marketing authorization application of their multiple sclerosis (MS) candidate, Zinbryta.
BIIB: 422.24 (-9.38), CBM: 39.63 (+4.04), ABBV: 58.54 (+0.30), ALKS: 60.97 (-1.55)
Teva, Horizon Snap Up Orphan-Disease Drugs
at Investor's Business Daily - Mon Mar 30, 10:12AM CDT
Drugmakers showed their appetite for orphan-disease drugs Monday, with two billion-dollar-plus deals sending stocks soaring. Israeli drug giant Teva Pharmaceutical Industries (TEVA) agreed to pay $101 a share in cash for Auspex Pharmaceuticals...
BIIB: 422.24 (-9.38), ESRX: 86.77 (+1.37), HZNP: 25.97 (+0.19), CVS: 103.21 (-0.62), ASPX: 100.27 (-0.09), TEVA: 62.30 (-0.22), HPTX: 45.90 (-0.08)
Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), HD: 113.61 (-1.02), RYL: 48.74 (-0.17), ALTR: 42.91 (+0.09), AMGN: 159.85 (-4.45), XOM: 85.00 (-0.63), INTC: 31.27 (-0.19), CELG: 115.28 (-4.74), LEN: 51.81 (+0.32), CVX: 104.98 (-1.92), TOL: 39.34 (+0.13), REGN: 451.48 (-8.30)
Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 120.77 (-3.12), BIIB: 422.24 (-9.38), KITE: 57.68 (-2.30), ONVO: 3.54 (+0.17), BIOC: 2.24 (-0.10)
European regulator validates Biogen's marketing application for Remicade biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:00AM CDT
JNJ: 100.60 (-0.95), BIIB: 422.24 (-9.38), AMGN: 159.85 (-4.45)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 422.24 (-9.38), GE: 24.81 (-0.31), PCYC: 255.95 (-0.48), MON: 112.54 (-0.84), FRPT: 19.43 (-0.62), HON: 104.31 (-0.60), KRFT: 87.11 (-3.50), INTC: 31.27 (-0.19), BWLD: 181.24 (-1.73), AIR: 30.70 (-0.76), KMX: 69.01 (-0.21), JACK: 95.92 (-1.12), YHOO: 44.44 (-0.51), SONC: 31.70 (-0.59), CMG: 650.54 (-4.82), ABBV: 58.54 (+0.30), REGN: 451.48 (-8.30), UNP: 108.31 (-1.78), DK: 39.75 (-0.16), YUM: 78.72 (-0.69), MU: 27.13 (+0.45), SWKS: 98.29 (-1.84), AMGN: 159.85 (-4.45), NXPI: 100.36 (-2.07), BA: 150.08 (-2.62), PLKI: 59.82 (-0.92), FRGI: 61.00 (-1.03), HAIN: 64.05 (-0.23), WWAV: 44.34 (-0.30), ZOES: 33.29 (+0.37), QRVO: 79.70 (-1.70), CBRL: 152.14 (-0.65), CNI: 66.87 (+0.64), NDLS: 17.44 (-0.10), MCD: 97.44 (-0.44), AVGO: 126.98 (-3.57)
Research and Markets: Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
Business Wire - Mon Mar 30, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l42g9r/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering.
JNJ: 100.60 (-0.95), BIIB: 422.24 (-9.38)
Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab
Business Wire - Mon Mar 30, 1:00AM CDT
Biogen (NASDAQ: BIIB) today announced the Marketing Authorization Application (MAA) for SB2, its biosimilar infliximab candidate using Remicade(R)1 as the reference product, has been validated for review by the European Medicines Agency (EMA). The MAA was submitted by the company's joint venture (JV) partner, Samsung Bioepis. This is the second MAA validated for review by the EMA as part of the joint venture. The first, SB4, a biosimilar etanercept candidate referencing Enbrel(R)2 , was validated for review earlier this year.
BIIB: 422.24 (-9.38)
Based on This Study, an Alzheimer's Disease Cure Could Be Around the Corner
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 29, 8:19AM CDT
Source: Alzheimer's Society, Facebook. While heart disease and cancer may be this nation's top two killers, it doesn't make the prospect of developing Alzheimer's any less terrifying. Based on statistics from the Alzheimer's Association, more...
BIIB: 422.24 (-9.38)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 120.77 (-3.12), BIIB: 422.24 (-9.38), ESRX: 86.77 (+1.37), GILD: 98.13 (-2.56), PFE: 34.79 (-0.21), AMGN: 159.85 (-4.45)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 27, 6:59PM CDT
Cramer will look for any inkling of growth when industrial stocks report earnings next week.
GD: 135.73 (-1.78), BIIB: 422.24 (-9.38), F: 16.14 (-0.02), LMT: 202.96 (-1.93), SHAK: 50.05 (+0.43), MON: 112.54 (-0.84), FRPT: 19.43 (-0.62), RTN: 109.25 (-1.74), NOC: 160.96 (-1.72), GMCR: 111.73 (-2.23), BWLD: 181.24 (-1.73), AIR: 30.70 (-0.76), JACK: 95.92 (-1.12), KMX: 69.01 (-0.21), SONC: 31.70 (-0.59), CMG: 650.54 (-4.82), REGN: 451.48 (-8.30), YUM: 78.72 (-0.69), MU: 27.13 (+0.45), SWKS: 98.29 (-1.84), NXPI: 100.36 (-2.07), PLKI: 59.82 (-0.92), FRGI: 61.00 (-1.03), CELG: 115.28 (-4.74), MS: 35.69 (-0.62), QRVO: 79.70 (-1.70), CBRL: 152.14 (-0.65), GILD: 98.13 (-2.56), NDLS: 17.44 (-0.10), GM: 37.50 (-0.18), MCD: 97.44 (-0.44), DOW: 47.98 (-0.70), AVGO: 126.98 (-3.57), LLL: 125.79 (-0.90)
Time To Load Up On Biogen?
Valuentum - at Seeking Alpha - Fri Mar 27, 3:43PM CDT
BIIB: 422.24 (-9.38)
Stocks Finish Lower for the Week as Fed Talk Spooks Investors
at The Street - Fri Mar 27, 3:20PM CDT
Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), BMRN: 124.62 (-4.51), MON: 112.54 (-0.84), IBB: 343.43 (-7.89), SOXX: 94.02 (-1.07), NXPI: 100.36 (-2.07), KMX: 69.01 (-0.21), AYI: 168.16 (-4.41), AA: 12.92 (-0.04), TXN: 57.18 (-0.82), ADI: 63.00 (-1.81), ALXN: 173.30 (-6.96), AVGO: 126.98 (-3.57), REGN: 451.48 (-8.30)
Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 51 mins ago
Biogen (BIIB) announced that the European Medicines Agency has accepted its biosimilar candidate SB2 for review.
BIIB: 422.24 (-9.38), CBM: 39.63 (+4.04), HSP: 87.84 (+0.12), NVS: 98.61 (-2.70)
Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
PR Newswire Europe - Tue Mar 31, 11:52AM CDT
DUBLIN, Mar. 30, 2015 /PRNewswire/ --Research and Markets
JNJ: 100.60 (-0.95), BIIB: 422.24 (-9.38)
Healthcare Hedge Fund Orbimed's Top Picks And New Move
Insider Monkey - Seeking Alpha - Tue Mar 31, 10:37AM CDT
By Usman Rafi According to a Schedule 13D Form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) by about 14%. The fund...
BIIB: 422.24 (-9.38), ICPT: 282.02 (-13.89), AMGN: 159.85 (-4.45), BMY: 64.50 (-1.26)
Insider Trading Alert - MTEX, BDL And BIIB Traded By Insiders
at The Street - Tue Mar 31, 9:15AM CDT
Stocks with insider trader activity include MTEX, BDL and BIIB
BIIB: 422.24 (-9.38), MTEX: 18.76 (+0.35), BDL: 32.01 (unch)
Strong Dollar Hurts Profit Forecasts In Long Term
Orit Nathan Mahalal - at Seeking Alpha - Tue Mar 31, 7:00AM CDT
BIIB: 422.24 (-9.38), ABX: 10.96 (-0.18), FB: 82.21 (-0.98), IBB: 343.43 (-7.89), GOOG: 548.00 (-4.03), UUP: 25.90 (+0.04), SPY: 206.43 (-1.82), QQQ: 105.60 (-1.13), KGC: 2.24 (-0.05), GLD: 113.66 (-0.09), ALXN: 173.30 (-6.96), DIA: 177.58 (-1.81), XLK: 41.44 (-0.43), GOOGL: 554.70 (-6.44), FXE: 105.71 (-0.61), IWM: 124.37 (-0.40), MSFT: 40.65 (-0.31), AAPL: 124.43 (-1.94), REGN: 451.48 (-8.30), GG: 18.12 (-0.07)
Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 5:09PM CDT
Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency has validated the marketing authorization application of their multiple sclerosis (MS) candidate, Zinbryta.
BIIB: 422.24 (-9.38), CBM: 39.63 (+4.04), ABBV: 58.54 (+0.30), ALKS: 60.97 (-1.55)
Teva, Horizon Snap Up Orphan-Disease Drugs
at Investor's Business Daily - Mon Mar 30, 10:12AM CDT
Drugmakers showed their appetite for orphan-disease drugs Monday, with two billion-dollar-plus deals sending stocks soaring. Israeli drug giant Teva Pharmaceutical Industries (TEVA) agreed to pay $101 a share in cash for Auspex Pharmaceuticals...
BIIB: 422.24 (-9.38), ESRX: 86.77 (+1.37), HZNP: 25.97 (+0.19), CVS: 103.21 (-0.62), ASPX: 100.27 (-0.09), TEVA: 62.30 (-0.22), HPTX: 45.90 (-0.08)
Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), HD: 113.61 (-1.02), RYL: 48.74 (-0.17), ALTR: 42.91 (+0.09), AMGN: 159.85 (-4.45), XOM: 85.00 (-0.63), INTC: 31.27 (-0.19), CELG: 115.28 (-4.74), LEN: 51.81 (+0.32), CVX: 104.98 (-1.92), TOL: 39.34 (+0.13), REGN: 451.48 (-8.30)
Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 120.77 (-3.12), BIIB: 422.24 (-9.38), KITE: 57.68 (-2.30), ONVO: 3.54 (+0.17), BIOC: 2.24 (-0.10)
European regulator validates Biogen's marketing application for Remicade biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:00AM CDT
JNJ: 100.60 (-0.95), BIIB: 422.24 (-9.38), AMGN: 159.85 (-4.45)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 422.24 (-9.38), GE: 24.81 (-0.31), PCYC: 255.95 (-0.48), MON: 112.54 (-0.84), FRPT: 19.43 (-0.62), HON: 104.31 (-0.60), KRFT: 87.11 (-3.50), INTC: 31.27 (-0.19), BWLD: 181.24 (-1.73), AIR: 30.70 (-0.76), KMX: 69.01 (-0.21), JACK: 95.92 (-1.12), YHOO: 44.44 (-0.51), SONC: 31.70 (-0.59), CMG: 650.54 (-4.82), ABBV: 58.54 (+0.30), REGN: 451.48 (-8.30), UNP: 108.31 (-1.78), DK: 39.75 (-0.16), YUM: 78.72 (-0.69), MU: 27.13 (+0.45), SWKS: 98.29 (-1.84), AMGN: 159.85 (-4.45), NXPI: 100.36 (-2.07), BA: 150.08 (-2.62), PLKI: 59.82 (-0.92), FRGI: 61.00 (-1.03), HAIN: 64.05 (-0.23), WWAV: 44.34 (-0.30), ZOES: 33.29 (+0.37), QRVO: 79.70 (-1.70), CBRL: 152.14 (-0.65), CNI: 66.87 (+0.64), NDLS: 17.44 (-0.10), MCD: 97.44 (-0.44), AVGO: 126.98 (-3.57)
Research and Markets: Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
Business Wire - Mon Mar 30, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l42g9r/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering.
JNJ: 100.60 (-0.95), BIIB: 422.24 (-9.38)
Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab
Business Wire - Mon Mar 30, 1:00AM CDT
Biogen (NASDAQ: BIIB) today announced the Marketing Authorization Application (MAA) for SB2, its biosimilar infliximab candidate using Remicade(R)1 as the reference product, has been validated for review by the European Medicines Agency (EMA). The MAA was submitted by the company's joint venture (JV) partner, Samsung Bioepis. This is the second MAA validated for review by the EMA as part of the joint venture. The first, SB4, a biosimilar etanercept candidate referencing Enbrel(R)2 , was validated for review earlier this year.
BIIB: 422.24 (-9.38)
Based on This Study, an Alzheimer's Disease Cure Could Be Around the Corner
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 29, 8:19AM CDT
Source: Alzheimer's Society, Facebook. While heart disease and cancer may be this nation's top two killers, it doesn't make the prospect of developing Alzheimer's any less terrifying. Based on statistics from the Alzheimer's Association, more...
BIIB: 422.24 (-9.38)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 120.77 (-3.12), BIIB: 422.24 (-9.38), ESRX: 86.77 (+1.37), GILD: 98.13 (-2.56), PFE: 34.79 (-0.21), AMGN: 159.85 (-4.45)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Mar 27, 6:59PM CDT
Cramer will look for any inkling of growth when industrial stocks report earnings next week.
GD: 135.73 (-1.78), BIIB: 422.24 (-9.38), F: 16.14 (-0.02), LMT: 202.96 (-1.93), SHAK: 50.05 (+0.43), MON: 112.54 (-0.84), FRPT: 19.43 (-0.62), RTN: 109.25 (-1.74), NOC: 160.96 (-1.72), GMCR: 111.73 (-2.23), BWLD: 181.24 (-1.73), AIR: 30.70 (-0.76), JACK: 95.92 (-1.12), KMX: 69.01 (-0.21), SONC: 31.70 (-0.59), CMG: 650.54 (-4.82), REGN: 451.48 (-8.30), YUM: 78.72 (-0.69), MU: 27.13 (+0.45), SWKS: 98.29 (-1.84), NXPI: 100.36 (-2.07), PLKI: 59.82 (-0.92), FRGI: 61.00 (-1.03), CELG: 115.28 (-4.74), MS: 35.69 (-0.62), QRVO: 79.70 (-1.70), CBRL: 152.14 (-0.65), GILD: 98.13 (-2.56), NDLS: 17.44 (-0.10), GM: 37.50 (-0.18), MCD: 97.44 (-0.44), DOW: 47.98 (-0.70), AVGO: 126.98 (-3.57), LLL: 125.79 (-0.90)
Time To Load Up On Biogen?
Valuentum - at Seeking Alpha - Fri Mar 27, 3:43PM CDT
BIIB: 422.24 (-9.38)
Stocks Finish Lower for the Week as Fed Talk Spooks Investors
at The Street - Fri Mar 27, 3:20PM CDT
Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), BMRN: 124.62 (-4.51), MON: 112.54 (-0.84), IBB: 343.43 (-7.89), SOXX: 94.02 (-1.07), NXPI: 100.36 (-2.07), KMX: 69.01 (-0.21), AYI: 168.16 (-4.41), AA: 12.92 (-0.04), TXN: 57.18 (-0.82), ADI: 63.00 (-1.81), ALXN: 173.30 (-6.96), AVGO: 126.98 (-3.57), REGN: 451.48 (-8.30)
